Physician profile
Matthew Patton
NPI 1164758496
$24,474.60
in general payments reported to CMS, 2019-2025
29 companies · $5,312 in 2025
The $5,312 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,105 · 2022: $7,096 · 2023: $2,955 · 2024: $3,007 · 2025: $5,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,491 · Consulting Fee: $2,200 · Travel and Lodging: $1,297 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,490.93 |
| Consulting Fee | $2,200.00 |
| Travel and Lodging | $1,297.02 |
| Education | $286.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $9,398.83 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $4,652.20 | 2021-2025 | Odomzo, Blu-U, Ilumya |
| Abbvie INC. | $2,151.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,245.53 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,072.64 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $859.82 | 2021-2025 | Tremfya |
| Genzyme Corporation | $630.04 | 2021-2025 | |
| Ucb, INC. | $544.36 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $436.53 | 2022-2024 | Vtama |
| Leo Pharma INC. | $410.65 | 2021-2025 | Adbry |
| Amgen INC. | $406.30 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $350.23 | 2022-2025 | Sotyktu |
| Pfizer INC. | $297.36 | 2021-2025 | |
| Kyowa Kirin, INC. | $281.01 | 2021-2025 | Poteligeo |
| Incyte Corporation | $238.98 | 2021-2025 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $231.61 | 2022 | |
| Almirall LLC | $223.88 | 2021-2023 | Seysara |
| Galderma Laboratories, L.P. | $190.78 | 2021-2025 | Nemluvio, Aklief |
| Vyne Pharmaceuticals INC. | $165.83 | 2021 | |
| Genentech USA, INC. | $145.04 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.85 | 2021-2024 | Siliq, Jublia |
| Organogenesis INC. | $99.34 | 2023-2025 | Puraply, Matrix, Via Matrix |
| Mayne Pharma Commercial LLC | $83.61 | 2021-2024 | |
| Biofrontera INC. | $77.25 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $38.07 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.01 | 2023-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $32.23 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $20.43 | 2024 | Ycanth |
| Kerecis Limited | $15.28 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.